Brief: Bellerophon Provides Clinical Program Update And Reports Third Quarter 2022 Financial Results
14/11/2022 13:40
Nov 14 (Reuters) - Bellerophon Therapeutics Inc
BLPH.O :
* BELLEROPHON PROVIDES CLINICAL PROGRAM UPDATE AND REPORTS
THIRD
QUARTER 2022 FINANCIAL RESULTS
* BELLEROPHON THERAPEUTICS INC - PHASE 3 REBUILD
REGISTRATIONAL
STUDY ENROLLMENT OF INOPULSE FOR TREATMENT OF FILD IS
APPROACHING COMPLETION
* BELLEROPHON THERAPEUTICS INC - REDUCED STUDY SIZE IS 140
FILD
PATIENTS WHO WILL BE TREATED WITH EITHER INOPULSE AT A DOSE OF
INO45 OR A PLACEBO
* BELLEROPHON THERAPEUTICS INC - RECEIVED FDA CLEARANCE TO
CONDUCT
PHASE 2 STUDY AND CO IS CURRENTLY ASSESSING NEXT STEPS FOR STUDY
* BELLEROPHON THERAPEUTICS INC - QTRLY LOSS PER SHARE$0.53
Source text for Eikon: ID:nGNX3kPNTt
Further company coverage: BLPH.O
Recent news on Bellerophon Therapeutics
See all newsBrief: Bellerophon Therapeutics Inc On October 12, 2023, Board Of Directors Approved Plan Of Liquidation And Dissolution Of Company
Bellerophon Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Bellerophon Therapeutics Inc expected to post a loss of 42 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Archer-Daniels-Midland, Nucor, Copper miners
U.S. STOCKS ON THE MOVE-Hubbell, Spire Global, FibroGen